Company intelligence / Profile preview
Shanghai Escugen Biotechnology Co., Ltd.
Shanghai, Shanghai, Chinaescugen.com.cn ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Escugen’s lead program ESG401—an anti-TROP2 ADC—has shown positive results in a first-in-human study for patients with locally advanced/metastatic solid tumors. The company has multiple programs advancing through clinical and preclinical development targeting various cancers using proprietary ADC technology platforms. Their EZWi-Fit® platform demonstrates improved efficacy and safety over existing technologies.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Antibody-drug conjugates (ADCs)monoclonal antibodiesCAR-T therapiesfusion proteins
- Industry
- Biotech
02
Drug pipeline
11 assets10 more assets in the full pipeline.
03
Partnerships
Levena Biopharma/Sorrento Therapeutics – co-development of ESG401 and shared global rights/patents on the productTOT BIOPHARM – strategic collaboration for late-stage development/commercialization of ADC drugs including manufacturing support in China/US/EU marketsForeseen Biotechnology – partnership to develop first-in-class ADCs including FS001 targeting novel antigens; Ipsen licensed global rights to FS001 which uses Escugen’s linker-payload technologyInxMed – license agreement to develop next-generation ADCs
Beyond the preview
Go deeper on Shanghai Escugen Biotechnology Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai Escugen Biotechnology Co., Ltd..